PER 1.35% 7.5¢ percheron therapeutics limited

Ann: Long COVID-19 strategic collaboration with US Experts, page-8

  1. 4,683 Posts.
    lightbulb Created with Sketch. 1086
    Actually, the FDA tox study feedback is due any week now...so don't have to wait months for news.

    I think this Long COVID study is for the IP - additional proteomics data to support the DMD and MS patents.

    Might grab more PR for the company than the DMD program

    .
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.